TYRA TYRA BIOSCIENCES INC revenue, earnings and financials
For the quarter ended June 30, 2026, TYRA BIOSCIENCES INC reported revenue of n/a, net income of −$45.6M and diluted EPS of −$0.69; for the fiscal year ended December 2025 revenue was n/a.
TYRA annual revenue and earnings
- Fiscal year ended Dec 2025: revenue n/a, gross profit n/a, operating income −$133M, net income −$120M (margin n/a), EPS −$2.01
- Fiscal year ended Dec 2024: revenue n/a, gross profit n/a, operating income −$104M, net income −$86.5M (margin n/a), EPS −$1.51
- Fiscal year ended Dec 2023: revenue n/a, gross profit n/a, operating income −$79.9M, net income −$69.1M (margin n/a), EPS −$1.62
- Fiscal year ended Dec 2022: revenue n/a, gross profit n/a, operating income −$58.9M, net income −$55.3M (margin n/a), EPS −$1.32
- Fiscal year ended Dec 2021: revenue n/a, gross profit n/a, operating income −$26.3M, net income −$26.3M (margin n/a), EPS −$1.91
TYRA quarterly revenue and earnings
- Quarter ended Jun 30, 2026: revenue n/a, net income −$45.6M, EPS −$0.69
- Quarter ended Mar 31, 2026: revenue n/a, net income −$39.3M, EPS −$0.64
- Quarter ended Dec 31, 2025 (from the annual report): revenue n/a, net income −$33.8M, EPS −$0.57
- Quarter ended Sep 30, 2025: revenue n/a, net income −$29.9M, EPS −$0.50
- Quarter ended Jun 30, 2025: revenue n/a, net income −$28.1M, EPS −$0.47
- Quarter ended Mar 31, 2025: revenue n/a, net income −$28.1M, EPS −$0.47
- Quarter ended Dec 31, 2024 (from the annual report): revenue n/a, net income −$25.6M, EPS −$0.43
- Quarter ended Sep 30, 2024: revenue n/a, net income −$24.0M, EPS −$0.41
- Quarter ended Jun 30, 2024: revenue n/a, net income −$18.7M, EPS −$0.32
- Quarter ended Mar 31, 2024: revenue n/a, net income −$18.2M, EPS −$0.35
- Quarter ended Dec 31, 2023 (from the annual report): revenue n/a, net income −$22.8M, EPS −$0.54
- Quarter ended Sep 30, 2023: revenue n/a, net income −$21.2M, EPS −$0.49
- Quarter ended Jun 30, 2023: revenue n/a, net income −$13.3M, EPS −$0.31
- Quarter ended Mar 31, 2023: revenue n/a, net income −$11.9M, EPS −$0.28
- Quarter ended Dec 31, 2022 (from the annual report): revenue n/a, net income −$12.9M, EPS −$0.30
- Quarter ended Sep 30, 2022: revenue n/a, net income −$12.5M, EPS −$0.30
- Quarter ended Jun 30, 2022: revenue n/a, net income −$15.1M, EPS −$0.36
- Quarter ended Mar 31, 2022: revenue n/a, net income −$14.8M, EPS −$0.36
- Quarter ended Dec 31, 2021 (from the annual report): revenue n/a, net income −$9.93M, EPS $3.33
- Quarter ended Sep 30, 2021: revenue n/a, net income −$6.64M, EPS −$0.72
TYRA cash flow, buybacks and dividends
- Fiscal year ended Dec 2025: operating cash flow −$95.1M, share buybacks n/a
- Fiscal year ended Dec 2024: operating cash flow −$69.8M, share buybacks n/a
- Fiscal year ended Dec 2023: operating cash flow −$50.1M, share buybacks n/a
- Fiscal year ended Dec 2022: operating cash flow −$50.3M, share buybacks n/a
- Fiscal year ended Dec 2021: operating cash flow −$23.7M, share buybacks n/a
TYRA balance sheet
- Jun 30, 2026: cash $73.8M, total assets $383M, total liabilities $29.7M, shareholders' equity $354M
- Mar 31, 2026: cash $85.0M, total assets $412M, total liabilities $24.5M, shareholders' equity $388M
- Dec 31, 2025: cash $77.4M, total assets $283M, total liabilities $23.4M, shareholders' equity $259M
- Sep 30, 2025: cash $62.0M, total assets $302M, total liabilities $21.3M, shareholders' equity $281M
- Jun 30, 2025: cash $98.5M, total assets $321M, total liabilities $19.4M, shareholders' equity $302M
- Mar 31, 2025: cash $101M, total assets $343M, total liabilities $19.9M, shareholders' equity $324M
- Dec 31, 2024: cash $92.0M, total assets $364M, total liabilities $20.4M, shareholders' equity $343M
- Sep 30, 2024: cash $104M, total assets $381M, total liabilities $18.3M, shareholders' equity $362M
Is TYRA profitable?
No. TYRA BIOSCIENCES INC lost $149M over the last four quarters.
What is TYRA's EPS?
Diluted earnings per share over the last four quarters were −$2.40; −$0.69 in the latest quarter.